Aprepitant Capsules — Class III drug recall D-0349-2019
Terminated recall by Glenmark Pharmaceuticals Inc., USA, reported 2018-12-26, distributed nationwide. Shortfill: Aprepitant capsules 40 mg is being recalled due to customer reports of missing capsule in the blist
| Recall number | D-0349-2019 |
|---|---|
| Product type | Drug |
| Classification | Class III |
| Status | Terminated |
| Voluntary or mandated | Voluntary |
| Recalling firm | Glenmark Pharmaceuticals Inc., USA, Mahwah, NJ, United States |
| Recall initiated | 2018-11-27 |
| Classified | 2019-01-07 |
| Reported by FDA | 2018-12-26 |
| Terminated | 2019-09-12 |
| Distributed | Nationwide (US) |
| Quantity | 5,016 blister |
| UPC / GTIN / UDI-DI | 00368462583401 |
| NDC | 68462-0112, 68462-0112-33, 68462-0583, 68462-0583-11, 68462-0583-40, 68462-0583-85, 68462-0584, 68462-0584-40, 68462-0584-58, 68462-0584-76, 68462-0585, 68462-0585-40, 68462-0585-76 |
| Lot numbers | 17180918 |
| Expiration dates | 2020-06-20 |
Product
Aprepitant Capsules, USP 40 mg, 1 capsule Unit Blister Pack, Rx Only, Manufactured in India for: Glenmark Pharmaceuticals Inc., USA Mahwah, NJ 07430. UPC 368462583401. NDC 68462-583-40
Reason for recall
Shortfill: Aprepitant capsules 40 mg is being recalled due to customer reports of missing capsule in the blister pack.
Machine access
This record, with every extracted code, the verbatim FDA record and provenance, is available from the recall API: GET https://api.data.aroqon.com/v1/recalls/D-0349-2019. Look up any UPC, UDI, NDC or lot with /v1/recalls/lookup?code=…. API docs · free and paid keys.
Source: U.S. Food and Drug Administration enforcement report via openFDA (CC0). Structured by Data Foundry (recall-structuring@2); last changed 2026-09-26. Not affiliated with or endorsed by FDA. Not medical or legal advice.